In a prospective analysis of 218,635 UK Biobank participants followed for a median 14.4 years, each standard deviation increase in the Metabolic Vulnerability Index (MVX) — a composite biomarker derived from plasma metabolomics capturing systemic inflammation and metabolic malnutrition — was associated with 9% higher risk of incident cardiometabolic disease (CMD), 11% higher risk of multimorbidity (two or more conditions including coronary heart disease, stroke, or type 2 diabetes), and 12% higher all-cause mortality risk. Multi-state modeling revealed consistent risk elevations across disease transitions, from CMD-free to single CMD to multimorbidity to death. MVX-multimorbidity associations were notably stronger in females and in the T2DM-first progression pattern.
This finding matters because composite metabolic-inflammatory indices have struggled to outperform simpler clinical markers like CRP or BMI in large cohorts. MVX's metabolomics foundation gives it mechanistic depth that traditional biomarkers lack, potentially capturing upstream metabolic dysfunction before clinical disease manifests. The female-specific amplification of multimorbidity risk is particularly intriguing and warrants mechanistic investigation. Practically, MVX could refine primary prevention targeting — identifying high-risk individuals years before diagnosis. Limitations are substantial: this is an observational cohort with residual confounding likely; UK Biobank participants skew healthier and wealthier than the general population; and plasma metabolomics isn't yet routine clinical infrastructure. Critically, this is a preprint posted to medRxiv and has not undergone peer review — effect sizes and subgroup findings could shift upon scrutiny. Overall, this represents a confirmatory-to-incremental advance pending replication.
